Introduction {#section5-1758835920927635}
============

Acute myeloid leukemia (AML) is a common hematologic malignancy characterized by excessive proliferation of hematopoietic stem and progenitor cells, accounting for approximately 20% of childhood leukemia cases.^[@bibr1-1758835920927635]^ The diagnostic classification of AML includes a combination of morphology, immunology, cytogenetics, and molecular biology.^[@bibr2-1758835920927635]^ Currently, the standard treatment protocol for AML is combination chemotherapy, and patients may also undergo allogeneic stem cell transplantation, especially in high-risk groups for induction failure or recurrence.^[@bibr3-1758835920927635][@bibr4-1758835920927635]--[@bibr5-1758835920927635]^ Among patients over the age of 60 years, a complete remission (CR) rate of 40% to 60% can be achieved, though only 5% to 15% can be cured.^[@bibr1-1758835920927635],[@bibr6-1758835920927635]^ For the large number of AML cases in children and adolescents, overall survival (OS) and CR rates are 67% and 93%, respectively.^[@bibr7-1758835920927635]^ Although the diagnostic technology and treatment protocol of AML have gradually improved, the cure rate for pediatric AML lags behind pediatric acute lymphoblastic leukemia, mostly due to relapse.^[@bibr8-1758835920927635],[@bibr9-1758835920927635]^ Therefore, there is an urgent need for optimizing therapeutic strategies to design personalized therapy for individual patients.

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor drug calicheamicin, represents a promising targeted therapy in AML.^[@bibr10-1758835920927635]^ In May 2000, GO was granted accelerated approval by the US Food and Drug Administration (FDA) for AML patients in first relapse who were not candidates for conventional chemotherapy.^[@bibr11-1758835920927635]^ However, GO has not demonstrated sufficient effect in different patient populations as a single agent; the overall response rate has been only 25--35%.^[@bibr12-1758835920927635][@bibr13-1758835920927635]--[@bibr14-1758835920927635]^ In 2010, Pfizer voluntarily withdrew the drug after a phase III trial that failed to demonstrate superior efficacy of GO.^[@bibr15-1758835920927635]^ Despite these setbacks, results from subsequent clinical trials administering GO at 3--6 mg/m^2^ per dose demonstrated clinical benefit compared with standard chemotherapy in children and adults with AML, and the US FDA announced re-approval of GO in September 2017.^[@bibr13-1758835920927635],[@bibr16-1758835920927635]^

Annexin A5 (ANXA5) is a member of the annexin family, which binds phospholipids in a calcium-dependent manner, playing major roles in regulating cellular growth, differentiation, inflammation, and signaling.^[@bibr17-1758835920927635],[@bibr18-1758835920927635]^ Under stress, *ANXA5* is produced and released into the extracellular medium or bloodstream, functioning as a physiological anticoagulant, anti-inflammatory, and anti-apoptotic agent by protecting stressed or dying cells from contact with inflammatory cells.^[@bibr17-1758835920927635],[@bibr19-1758835920927635]^ A previous study showed that abnormal expression patterns of *ANXA5* are associated with proliferation, invasion, drug resistance, and tumor treatment.^[@bibr20-1758835920927635][@bibr21-1758835920927635][@bibr22-1758835920927635]--[@bibr23-1758835920927635]^ Furthermore, annexin family members have distinct prognostic roles in adult and pediatric AML. High expression levels of *ANXA2, ANXA6*, and *ANXA7* have been associated with worse prognoses of patients with AML, whereas *ANXA5* has been correlated with more favorable clinical outcomes.^[@bibr24-1758835920927635],[@bibr25-1758835920927635]^ Nevertheless, the relevance of annexin family members as predictive molecular markers to guide treatment choice remains largely unexplored.

In this study, we compared GO-containing treatment regimens with non-GO regimens in pediatric patients with AML. From the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database, a gene expression pattern associated with *ANXA5* expression was derived to investigate pediatric AML. *ANXA5* was identified as a gene that may circumvent poor outcomes in pediatric patients with AML treated with GO. Finally, our study revealed that expression of *ANXA5* can help optimize the treatment regimen for individual patients.

Materials and methods {#section6-1758835920927635}
=====================

Patients {#section7-1758835920927635}
--------

A total of 253 patients aged 0--24 years and diagnosed with pediatric/adolescent AML were included in this study. The clinical data and treatment of the patients were analyzed retrospectively for receiving conventional chemotherapy (no-GO group, *n* = 95) or the same chemotherapy regimen combined with a dose of 3 mg/m^2^ GO (GO group, *n* = 158). The datasets used in this investigation were acquired from the publicly available TARGET database (<https://ocg.cancer.gov/>), and clinical outcome data were included in Children's Oncology Group trials AAML0531 and AAML03P1.^[@bibr26-1758835920927635],[@bibr27-1758835920927635]^ Data were downloaded and analyzed until 20 June 2019 in this study. Exclusion criteria were as follows: (1) samples without clinical data, (2) samples without complete gene expression data and survival period, and (3) patients with acute promyelocytic leukemia, Down syndrome, or secondary/treatment-related leukemia. As the data were obtained from a publicly available database, further approval from the local ethics committee was not required.

Gene expression profiling {#section8-1758835920927635}
-------------------------

We used Perl language (<https://www.perl.org/>; version 5.30.0) to extract the gene matrix file, including *ANXA5* expression data and match gene expression array with clinical long-term follow-up data. Then, the Ensembl IDs were transformed into gene names based on the Ensembl database (<http://www.ensembl.org>). Patients with FLT3-ITD mutations were classified as either positive or negative.^[@bibr28-1758835920927635],[@bibr29-1758835920927635]^ The Search Tool for the Retrieval of Interacting Genes (STRING 11.0; <https://string-db.org/>) was used to predict proteins interacting with a query protein.^[@bibr30-1758835920927635]^ In the present study, the following parameters were selected: hiding disconnected nodes in the network; medium confidence score \> 0.400; no more than 20 interactions. The "pheatmap" package in R 3.5.2 software (<https://www.r-project.org/>) was used to construct a heat map of coexpression patterns of *ANXA5*. The Cancer Cell Line Encyclopedia (CCLE; <https://portals.broadinstitute.org/ccle/about>) dataset was used to analyze *ANXA5* expression in cancer cell lines.^[@bibr31-1758835920927635]^

Gene set enrichment analysis {#section9-1758835920927635}
----------------------------

Gene set enrichment analysis (GSEA) is a knowledge-based method that determines whether a particular set of functionally related genes shows statistically significant, concordant differences between two biological states.^[@bibr32-1758835920927635]^ In this study, we used GSEA version 4.0.1 software (<http://software.broadinstitute.org/gsea/>). The 253 AML samples in this investigation were divided into a low- or high-expression group using *ANXA5* median expression level as a cut-off point. To identify potential mechanisms underlying the effects of gene expression, the expression level of *ANXA5* was used as a phenotype label, and gene set permutations were performed 1000 times for each analysis. Finally, the pathways enriched in each phenotype were sorted by normalized enrichment score (NES) and nominal *p*-value.

Statistical analysis {#section10-1758835920927635}
--------------------

Statistical analysis was performed using GraphPad Prism software (version 8.02; GraphPad Software, Inc., La Jolla, CA, USA). Clinical and molecular characteristics of patients were described by median and/or range. Comparisons between continuous variables were analyzed using the Mann--Whitney *U* test, and the chi-square test or Fisher's exact test were used to compare differences in proportions of variables among groups. OS was defined as the time period from diagnosis to death or the date of last follow up. EFS was defined as the time from diagnosis to relapse, induction failure, death in remission, or the date of last follow up. OS and EFS were estimated by Kaplan--Meier analysis and log-rank test. Univariate and multivariate Cox proportional hazard models were constructed to analyze the impact of clinical prognostic factors in pediatric AML, and to estimate the hazard ratios (HRs) and their 95% confidence interval (CI). The level of statistical significance was set at *p* \< 0.05.

Results {#section11-1758835920927635}
=======

Patient characteristics {#section12-1758835920927635}
-----------------------

To establish correlations between *ANXA5* expression and various clinical characteristics in pediatric AML, we assigned patients who underwent chemotherapy combined with ±GO to one of two groups, according to median *ANXA5* expression levels, respectively. Details on the clinical and molecular characteristics of patients in both groups are summarized in [Table 1](#table1-1758835920927635){ref-type="table"}. The median age was 10.4 (range 0.1--23.5) years. In the no-GO treatment group, participants who exhibited downregulated *ANXA5* had a higher percentage of *WT1* mutation compared with upregulated *ANXA5* expression (*p* = 0.016). In addition, high *ANXA5* expression often had more *MLL* (*p* = 0.008) or *CBFβ-MYH11* (*p* = 0.002) mutations and fewer *RUNX1-RUNX1T1* (*p* = 0.004) fusions. Moreover, patients with lower *ANXA5* expression had higher peripheral blood myeloblast counts (*p* = 0.007), though the median was not different between the two groups. Between the high and low *ANXA5* expression groups, no significant differences were observed in age, sex, ethnicity, white blood cell count, bone marrow blast, complex karyotype, or *FLT3-ITD, NPM1, CEBPA*, and c-KIT mutations in exons 8 and 17. In the GO treatment group, study participants with downregulated *ANXA5* exhibited a higher frequency of *CEBPA* (*p* = 0.005) and *FLT3-ITD* (*p* = 0.022) mutations, whereas c-Kit mutations in exons 17 (*p* = 0.007) and white blood cell counts (*p* = 0.001) were lower. Overall, the clinical and molecular characteristics of the two treatment groups at diagnosis were similar ([Supplemental Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1758835920927635)), excluding the influence of *ANXA5* expression. Interestingly, both treatment groups showed that patients with low *ANXA5* expression were more often diagnosed with M1 or M2 compared with patients with high *ANXA5* expression.

###### 

Comparison of clinical and molecular characteristics with *ANXA5* expression in patients.

![](10.1177_1758835920927635-table1)

  Characteristic                                                   [No gemtuzumab ozogamicin treatment]{.ul}   [Gemtuzumab ozogamicin treatment]{.ul}                                                                                                          
  ---------------------------------------------------------------- ------------------------------------------- ---------------------------------------- --------------------------------------------------------------- ------------------ ------------------- ---------------------------------------------------------------
  **Age/years, median (range)**                                    10.6 (0.1--20.3)                            10.3 (1.7--23.5)                         0.101^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^   10.4 (0.4--22.5)   10.3 (1.2--18.2)    0.448^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^
  **Age group/*n* (%)**                                                                                                                                 0.612^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.633^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   \<10 years                                                      23 (48.9)                                   21 (43.8)                                                                                                40 (50.6)          37 (46.8)           
   ⩾10 years                                                       24 (51.1)                                   27 (56.2)                                                                                                39 (49.4)          42 (53.2)           
  **Sex/*n* (%)**                                                                                                                                       0.051^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.076^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Male                                                            19 (40.4)                                   30 (62.5)                                                                                                52 (65.8)          40 (50.6)           
   Female                                                          28 (59.6)                                   18 (37.5)                                                                                                27 (34.2)          39 (49.4)           
  **Ethnicity/*n*(%)**                                                                                                                                                                                                                                         
   Hispanic or Latino                                              11 (23.4)                                   10 (20.8)                                0.763^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    14 (17.7)          16 (20.3)           0.685^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Not Hispanic or Latino                                          32 (68.1)                                   36 (75.0)                                0.455^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    63 (79.7)          61 (77.2)           0.699^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Unknown                                                         4 (8.5)                                     2 (4.2)                                  0.384^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    2 (2.5)            2 (2.5)             1.000^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  **WBC/×10** ^[@bibr9-1758835920927635]^ **/l, median (range)**   33.5 (1.3--519)                             34.6 (0.9--439.2)                        0.183^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^   53.5 (4.2--446)    52.6 (1.5--263.1)   0.001^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^
  **BM blast/%, median (range)**                                   71 (23--99)                                 71 (20--99)                              0.961^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^   77 (21--100)       77 (21--99)         0.885^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^
  **PB blast/%, median (range)**                                   62 (0--97)                                  62 (2--97)                               0.007^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^   61 (0--95)         61 (0--97)          0.792^[\*](#table-fn2-1758835920927635){ref-type="table-fn"}^
  **FAB subtypes/*n* (%)**                                                                                                                                                                                                                                     
   M0                                                              0 (0)                                       2 (4.2)                                  0.157^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    2 (2.5)            4 (5.1)             0.405^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M1                                                              3 (6.4)                                     10 (20.8)                                0.040^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    3 (3.8)            16 (20.3)           0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M2                                                              4 (8.5)                                     19 (39.6)                                0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    8 (10.1)           26 (32.9)           0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M4                                                              10 (21.3)                                   4 (8.3)                                  0.075^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    35 (44.3)          8 (10.1)            0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M5                                                              14 (29.8)                                   2 (4.2)                                  0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    23 (29.1)          9 (11.4)            0.006^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M6                                                              0 (0)                                       1 (2.1)                                  0.319^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    0 (0)              2 (2.5)             0.155^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   M7                                                              5 (10.6)                                    1 (2.1)                                  0.087^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    1 (1.3)            1 (1.3)             1.000^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Others                                                          11 (23.4)                                   9 (18.6)                                 0.578^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    7 (8.9)            13 (16.5)           0.151^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  **Cytogenetics/*n* (%)**                                                                                                                                                                                                                                     
   Normal                                                          9 (19.1)                                    11 (22.9)                                0.652^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    17 (21.5)          28 (35.4)           0.056^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Complex karyotype                                               7 (14.9)                                    7 (14.6)                                 0.966^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    12 (15.2)          11 (13.9)           0.822^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   inv(16)/*CBFβ-MYH11*                                            11 (23.4)                                   1 (2.1)                                  0.002^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    23 (29.1)          1 (1.3)             0.001^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   11q23/*MLL*                                                     14 (29.8)                                   4 (8.3)                                  0.008^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    14 (17.7)          9 (11.4)            0.259^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   t(8;21)/*RUNX1-RUNX1T1*                                         3 (6.4)                                     14 (29.2)                                0.004^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    5 (6.3)            16 (20.3)           0.010^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Others                                                          3 (6.4)                                     11 (22.9)                                0.023^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    8 (10.1)           14 (17.7)           0.168^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  **Risk/*n* (%)**                                                                                                                                                                                                                                             
   Good                                                            18 (38.2)                                   21 (43.7)                                0.589^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    33 (41.8)          31 (39.2)           0.746^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Intermediate                                                    27 (57.4)                                   19 (39.5)                                0.082^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    35 (44.3)          34 (43.0)           0.873^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Poor                                                            2 (4.2)                                     8 (16.6)                                 0.049^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    7 (8.9)            1 0 (12.7)          0.441^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Others                                                          0 (0)                                       0 (0)                                    1.000^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    4 (5.1)            4 (5.1)             1.000^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  ***FLT3-ITD*/*n* (%)**                                                                                                                                0.473^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.022^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Positive                                                        8 (17.0)                                    11 (22.9)                                                                                                6 (7.6)            16 (20.3)           
   Negative                                                        39 (83.0)                                   37 (77.1)                                                                                                73 (92.4)          63 (79.7)           
  ***NPM1*/*n* (%)**                                                                                                                                    0.751^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.548^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Mutation                                                        4 (8.5)                                     5 (10.4)                                                                                                 7 (8.9)            5 (6.3)             
   Wild type                                                       43 (91.5)                                   43 (89.6)                                                                                                72 (91.1)          74 (93.7)           
  ***CEBPA*/*n* (%)**                                                                                                                                   0.176^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.005^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Mutation                                                        1 (2.1)                                     4 (8.3)                                                                                                  1 (1.3)            10 (12.7)           
   Wild type                                                       46 (97.9)                                   44 (91.7)                                                                                                78 (98.7)          69 (87.3)           
  ***WT1*/*n* (%)**                                                                                                                                     0.016^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.148^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Mutation                                                        1 (2.1)                                     8 (16.7)                                                                                                 4 (5.1)            9 (11.4)            
   Wild type                                                       46 (97.9)                                   40 (83.3)                                                                                                75 (94.9)          70 (88.6)           
  **c-Kit mutation exon 8/*n* (%)**                                                                                                                                                                                                                            
   Yes                                                             4 (8.5)                                     2 (4.2)                                  0.384^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    3 (3.8)            5 (6.3)             0.468^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   No                                                              10 (21.3)                                   13 (27.1)                                0.509^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    20 (25.3)          10 (12.7)           0.043^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Not done                                                        33 (70.2)                                   33 (68.8)                                0.878^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    56 (70.9)          64 (81.0)           0.136^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  **c-Kit mutation exon 17/*n* (%)**                                                                                                                                                                                                                           
   Yes                                                             2 (4.3)                                     5 (10.4)                                 0.250^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    7 (8.9)            0 (0)               0.007^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   No                                                              12 (25.5)                                   10 (20.8)                                0.587^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    16 (20.3)          15 (19.0)           0.841^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Not done                                                        33 (70.2)                                   33 (68.8)                                0.878^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    56 (70.9)          64 (81.0)           0.136^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
  **CNS disease/*n* (%)**                                                                                                                               0.570^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^                                           0.230^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Yes                                                             1 (2.1)                                     2 (4.2)                                                                                                  4 (5.1)            8 (10.1)            
   No                                                              46 (97.9)                                   46 (95.8)                                                                                                75 (94.9)          71 (89.9)           
  **CR1 achieved/*n* (%)**                                                                                                                                                                                                                                     
   Yes                                                             31 (66.0)                                   31 (64.6)                                0.888^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    70 (88.6)          60 (75.9)           0.037^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   No                                                              15 (31.9)                                   17 (35.4)                                0.718^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    9 (11.4)           19 (24.1)           0.037^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^
   Unevaluable                                                     1 (2.1)                                     0 (0)                                    0.310^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^    0 (0)              0 (0)               1.000^[§](#table-fn3-1758835920927635){ref-type="table-fn"}^

BM, bone marrow; CNS, central nervous system; CR1, first complete remission; FAB, French American British; PB, peripheral blood; WBC, white blood cell.

denotes Mann--Whitney *U* test.

denotes chi-square test. Complex karyotype is defined as more than or equal to three chromosomal abnormalities.

Prognostic value of *ANXA5* expression {#section13-1758835920927635}
--------------------------------------

A log-rank test of Kaplan--Meier curves was used to describe the differences in survival to estimate clinical outcomes of *ANXA5* in patients with different chemotherapy regimens. In the no-GO treatment group, survival distribution curves demonstrated that high *ANXA5* expressers had shorter OS (HR = 2.086, 95% CI 1.158--3.758, *p* = 0.0141) and EFS (HR = 2.211, 95% CI 1.225--3.991, *p* = 0.0077) than low expressers \[[Figure 1(a and b)](#fig1-1758835920927635){ref-type="fig"}\]. However, high expression of *ANXA5* was considered a favorable prognostic factor for OS (HR = 0.583, 95% CI 0.352--0.939, *p* = 0.0277) and EFS (HR = 0.545, 95% CI 0.338--0.878, *p* = 0.0126) in patients with AML who received GO treatment \[[Figure 1(c and d)](#fig1-1758835920927635){ref-type="fig"}\]. These results suggest that the curative effect of GO treatment may be closely related to the level of *ANXA5* expression regulation in pediatric AML.

![Kaplan--Meier curves of survival in pediatric AML patients with respect to *ANXA5* expression. (a, b) Effect of *ANXA5* expression on OS and EFS in the no-GO treatment group (*n* = 95). (c, d) Patients with high *ANXA5* expression had significantly prolonged OS and EFS in the GO treatment group (*n* = 158).\
AML, acute myeloid leukemia; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival.](10.1177_1758835920927635-fig1){#fig1-1758835920927635}

Univariate and multivariate analyses for prognostic factors {#section14-1758835920927635}
-----------------------------------------------------------

To evaluate the impact of clinical and molecular factors associated with *ANXA5* expression level in pediatric AML, Cox proportional hazard models were constructed. The variables included expression levels of *ANXA5* (high *versus* low), age (⩾10 *versus* \<10 years), sex (male *versus* female), white blood cells (⩾50 *versus* \<50 × 10^9^/l), bone marrow blasts (⩾70% *versus* \<70%), peripheral blood blasts (⩾50% *versus* \<50%), *NPM1* (mutated *versus* wild type), *MLL* (mutated *versus* wild type), *FLT3-ITD* (positive *versus* negative), *CBFβ-MYH11* (positive *versus* negative), *RUNX1-RUNX1T1* (positive *versus* negative), *WT1* (mutated *versus* wild type), and risk (poor *versus* non-poor). A forest plot was constructed for OS for all patients according to prognostic factors ([Figure 2](#fig2-1758835920927635){ref-type="fig"}), and the results showed that favorable factors in pediatric AML were found in terms of *RUNX1-RUNX1T1, CBFβ-MYH11, NPM1* mutation, and *CEBPA* mutation, consistent with the results of the current risk stratification criteria.^[@bibr33-1758835920927635]^ Meanwhile, we developed a nomogram to predict the probability of the 1- and 5-year OS including *ANXA5* and clinical--biological prognostic index (see [Figure 3](#fig3-1758835920927635){ref-type="fig"}).

![Forest plot of HR for OS according to prognostic factors with all patients with AML. Multivariate analyses of age, sex, CNS disease, *DEK-NUP214, RUNX1-RUNX1T1, CBFB-MYH11, FLT3-ITD*, complex karyotype, *MLL, NPM1* mutation, *CEBPA* mutation, *WT1* mutation, GO treatment and *ANXA5* expression group for OS in all patients. The black squares on the transverse lines represent the HR, and the gray transverse lines represent 95% CI.\
AML, acute myeloid leukemia; CI, confidence interval; CNS, central nervous system; GO, gemtuzumab ozogamicin; HR, hazard ratio; OS, overall survival.\
\**p* \< 0.05 and \*\*p \< 0.01.](10.1177_1758835920927635-fig2){#fig2-1758835920927635}

![Nomogram for the prediction of OS at 1-, 3- and 5-years according to the clinical--biological prognostic index in patients with pediatric AML. By adding up the points assigned to each predictive variable, the total score on the bottom scale shows the probability of survival.\
AML, acute myeloid leukemia; OS, overall survival.](10.1177_1758835920927635-fig3){#fig3-1758835920927635}

In the no-GO treatment group, univariate analysis showed that high *ANXA5* expression was associated with shorter OS (HR = 2.097, 95% CI 1.146--3.838, *p* = 0.016) and EFS (HR = 2.232, 95% CI 1.218--4.093, *p* = 0.009). Furthermore, multivariate analysis indicated that *ANXA5* upregulation was an independent risk factor for OS (HR = 2.687, 95% CI 1.355--5.326, *p* = 0.005) and EFS (HR = 2.762, 95% CI 1.365--5.591, *p* = 0.005). Results are shown in [Table 2](#table2-1758835920927635){ref-type="table"}.

###### 

Univariate and multivariate analysis for EFS and OS in patients without gemtuzumab ozogamicin treatment.

![](10.1177_1758835920927635-table2)

  Variables                                         OS                     EFS                            
  ------------------------------------------------- ---------------------- ------- ---------------------- -------
  **Univariate analyses**                                                                                 
   *ANXA5* (high *versus* low)                      2.097 (1.146--3.838)   0.016   2.232 (1.218--4.093)   0.009
   Age (⩾10 *versus* \<10 years)                    1.017 (0.565--1.833)   0.954   0.948 (0.526--1.709)   0.859
   Sex (male *versus* female)                       1.288 (0.715--2.32)    0.399   1.271 (0.706--2.289)   0.425
   Ethnicity (Hispanic or Latino *versus* others)   1.657 (0.854--3.213)   0.135   1.507 (0.777--2.924)   0.225
   WBC (⩾50 *versus* \<50 × 10^9^/l)                1.003 (0.552--1.821)   0.992   1.315 (0.723--2.393)   0.37
   BM blasts (⩾70 *versus* \<70%)                   0.957 (0.532--1.72)    0.883   0.979 (0.545--1.76)    0.943
   PM blasts (⩾50 *versus* \<50%)                   0.718 (0.395--1.305)   0.277   0.865 (0.476--1.571)   0.634
   *NPM1* (mutated *versus* wild type)              0.578 (0.179--1.867)   0.36    0.547 (0.169--1.767)   0.313
   *MLL* (mutated *versus* wild type)               1.807 (0.869--3.756)   0.113   1.683 (0.809--3.5)     0.163
   *FLT3-ITD* (positive *versus* negative)          1.163 (0.576--2.351)   0.673   1.288 (0.637--2.603)   0.481
   *CBFβ-MYH11* (positive *versus* negative)        0.598 (0.214--1.669)   0.326   0.687 (0.245--1.925)   0.476
   *RUNX1-RUNX1T1* (positive *versus* negative)     0.507 (0.2--1.284)     0.152   0.404 (0.159--1.026)   0.057
   *WT1* (mutated *versus* wild type)               1.211 (0.433--3.385)   0.715   1.4 (0.498--3.933)     0.523
   Risk (poor *versus* non-poor)                    2.795 (1.415--5.521)   0.003   3.259 (1.646--6.449)   0.001
  **Multivariate analyses**                                                                               
   *ANXA5* (high *versus* low)                      2.687 (1.355--5.326)   0.005   2.762 (1.365--5.591)   0.005
   Ethnicity (Hispanic or Latino *versus* others)   1.652 (0.845--3.231)   0.142   1.408 (0.722--2.746)   0.315
   *MLL* (mutated *versus* wild type)               0.783 (0.335--1.828)   0.572   0.709 (0.309--1.626)   0.417
   *FLT3-ITD* (positive *versus* negative)          1.343 (0.62--2.912)    0.455   1.535 (0.696--3.383)   0.288
   *RUNX1-RUNX1T1* (positive *versus* negative)     2.009 (0.572--7.06)    0.277   1.884 (0.513--6.923)   0.34
   Risk (poor *versus* non-poor)                    3.806 (1.518--9.542)   0.004   4.492 (1.781--11.33)   0.001

BM, bone marrow; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; PB, peripheral blood; PM, peripheral blood; non-poor, intermediate and good; WBC, white blood cell.

In the GO treatment group, univariate analysis showed that high *ANXA5* expression was associated with longer OS (HR = 0.583, 95% CI 0.359--0.948, *p* = 0.030) and EFS (HR = 0.544, 95% CI 0.334--0.884, *p* = 0.014), as well as *CBFβ/MYH11*-positive for OS (HR = 0.364, 95% CI 0.146--0.906, *p* = 0.030) and EFS (HR = 0.356, 95% CI 0.143--0.885, *p* = 0.026). In addition, multivariate analysis showed that high *ANXA5* expression was an independent favorable factor for OS (HR = 0.629, 95% CI 0.372--1.064, *p* = 0.084) and EFS (HR = 0.544, 95% CI 0.321--0.922, *p* = 0.024) in combination with the curative effect of GO treatment. Results are shown in [Table 3](#table3-1758835920927635){ref-type="table"}.

###### 

Univariate and multivariate analysis for EFS and OS in patients with gemtuzumab ozogamicin treatment.

![](10.1177_1758835920927635-table3)

  Variables                                         OS                     EFS                            
  ------------------------------------------------- ---------------------- ------- ---------------------- -------
  **Univariate analyses**                                                                                 
   *ANXA5* (high *versus* low)                      0.583 (0.359--0.948)   0.03    0.544 (0.334--0.884)   0.014
   Age (⩾10 *versus* \<10 years)                    1.105 (0.687--1.778)   0.68    0.956 (0.594--1.539)   0.853
   Sex (male *versus* female)                       0.524 (0.325--0.845)   0.008   0.538 (0.334--0.867)   0.011
   Ethnicity (Hispanic or Latino *versus* others)   1.19 (0.661--2.142)    0.563   1.179 (0.655--2.124)   0.582
   WBC (⩾50 *versus* \<50 × 10*9*/l)                0.725 (0.449--1.17)    0.188   0.711 (0.441--1.148)   0.163
   BM blasts (⩾70 *versus* \<70%)                   0.947 (0.584--1.536)   0.827   0.906 (0.558--1.47)    0.688
   PM blasts (⩾50 *versus* \<50%)                   0.981 (0.601--1.6)     0.938   0.905 (0.554--1.476)   0.688
   *NPM1* (mutated *versus* wild type)              0.328 (0.08--1.34)     0.121   0.303 (0.074--1.237)   0.096
   *MLL* (mutated *versus* wild type)               1.274 (0.632--2.57)    0.499   1.291 (0.64--2.603)    0.476
   *FLT3-ITD* (positive *versus* negative)          1.546 (0.81--2.954)    0.187   1.483 (0.777--2.829)   0.232
   *CBFβ-MYH11* (positive *versus* negative)        0.364 (0.146--0.906)   0.03    0.356 (0.143--0.885)   0.026
   *RUNX1-RUNX1T1* (positive *versus* negative)     0.545 (0.236--1.261)   0.156   0.528 (0.228--1.222)   0.136
   *WT1* (mutated *versus* wild type)               1.935 (0.923--4.056)   0.08    2.208 (1.052--4.632)   0.036
   Risk (poor *versus* non-poor)                    3.115 (1.815--5.346)   0.001   3.451 (2.009--5.928)   0.001
  **Multivariate analyses**                                                                               
   *ANXA5* (high *versus* low)                      0.629 (0.372--1.064)   0.084   0.544 (0.321--0.922)   0.024
   *NPM1* (mutated *versus* wild type)              0.432 (0.103--1.811)   0.251   0.409 (0.098--1.701)   0.219
   *CBFβ-MYH11* (positive *versus* negative)        0.9 (0.297--2.729)     0.852   1.034 (0.34--3.143)    0.953
   *WT1* (mutated *versus* wild type)               1.569 (0.735--3.35)    0.244   1.753 (0.822--3.738)   0.146
   Risk (poor *versus* non-poor)                    2.778 (1.476--5.228)   0.002   3.323 (1.764--6.26)    0.001

BM, bone marrow; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; PB, peripheral blood; PM, peripheral blood; non-poor, intermediate and good; WBC, white blood cell.

Patients overexpressing *ANXA5* benefited from GO treatment {#section15-1758835920927635}
-----------------------------------------------------------

The 253 patients were divided into two groups based on median expression levels of *ANXA5* in order to investigate whether GO treatment could overcome the unfavorable outcomes of high *ANXA5* expression in pediatric AML. In the high *ANXA5* expression group, the patients undergoing chemotherapy combined with GO had significantly better OS (*p* = 0.0012) and EFS (*p* = 0.0003) compared with patients treated with conventional chemotherapy alone \[[Figure 4(a and b)](#fig4-1758835920927635){ref-type="fig"}\]. For the low *ANXA5* expression group, there were no obvious differences in OS (*p* = 0.0679) regardless of whether or not the chemotherapy regimen was combined with GO \[[Figure 4(c)](#fig4-1758835920927635){ref-type="fig"}\]. However, low expression of *ANXA5* might be considered an unfavorable prognostic factor in EFS (*p* = 0.0441) under GO treatment \[[Figure 4(d)](#fig4-1758835920927635){ref-type="fig"}\]. Pediatric AML patients with overexpression of *ANXA5* may circumvent poor outcomes from chemotherapy combined with GO.

![GO treatment circumvents the unfavorable outcomes of high *ANXA5* expression in pediatric AML patients. A total of 253 patients were divided into two groups based on the median expression levels of *ANXA5*. (a, b) Kaplan--Meier curves of OS and EFS in patients with GO treatment (*n* = 80) and without GO treatment (*n* = 46) in the high-*ANXA5*-expression group. (c, d) Kaplan--Meier curves of OS and EFS in patients with GO treatment (*n* = 78) and without GO treatment (*n* = 49) in the low-*ANXA5*-expression group.\
AML, acute myeloid leukemia; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival.](10.1177_1758835920927635-fig4){#fig4-1758835920927635}

Biological insights {#section16-1758835920927635}
-------------------

To generate insight into the biological functions of *ANXA5* among pediatric patients with AML, we analyzed the features of gene expression connected with *ANXA5* expression. An association between the expression of the most frequently altered neighbor genes and *ANXA5* was observed; the network is shown in [Figure 5(a)](#fig5-1758835920927635){ref-type="fig"}. In addition, we extracted the gene matrix file including immune-related genes in pediatric AML, and a heat map of genes coexpressed with *ANXA5* expression level was constructed. Among these genes, 7 were negatively correlated and 26 were positively correlated with the expression of *ANXA5* \[[Figure 5(b)](#fig5-1758835920927635){ref-type="fig"}\]. The results showed that *ANXA5* expression was positively correlated with the expression of *ANXA2, HMOX1, CD4, CD14, C3*, and *MAP2K1*, as well as *HLA-B* and *HLA-C*. Notably, these molecular markers are crucial for the leukemogenesis and immune functions of regulation in AML.^[@bibr34-1758835920927635],[@bibr35-1758835920927635]^ [Figure 5(c)](#fig5-1758835920927635){ref-type="fig"} shows the expression of *ANXA5* in different tumor cell lines according to the CCLE database.

![Analysis of *ANXA5* gene expression. (a) The network for *ANXA5* and the most frequently altered neighbor genes, analyzed by STRING. (b) Immune-related genes coexpressed of heat map with *ANXA5* in pediatric AML. (c) The expression of *ANXA5* in tumor cell lines, analyzed by CCLE.\
AML, acute myeloid leukemia; CCLE, the Cancer Cell Line Encyclopedia; STRING, Search Tool for the Retrieval of Interacting Genes.](10.1177_1758835920927635-fig5){#fig5-1758835920927635}

To understand the functional biological implications of aberrantly expressed *ANXA5* in pediatric AML, a top 10 gene ontology enrichment analysis was conducted. Relevant biological processes included were neutrophil activation, neutrophil-mediated immunity, phagocytosis, and innate immune-response-activating signal transduction. Furthermore, the most enriched gene ontology terms in cellular component included lysosomal lumen and secretory granule membrane; in molecular function, the most enriched terms were immunoglobulin binding, cytokine receptor activity, and signaling pattern recognition receptor activity. The results of the bubble diagram are shown in [Figure 6](#fig6-1758835920927635){ref-type="fig"}.

![Gene ontology terms of biological processes, cellular component, and molecular function in the *ANXA5* associated expression profile with pediatric AML. The size of each dot represents the count of genes, the color represents the adjusted *p*-value.\
AML, acute myeloid leukemia.](10.1177_1758835920927635-fig6){#fig6-1758835920927635}

To explore signaling pathways in which *ANXA5* is differentially activated in pediatric AML, we performed GSEA between high and low *ANXA5* expression data sets. GSEA revealed significant differences (nominal \< 0.05, false discovery rate *p* \< 0.05) in the gene expression profile from the MSigDB collection (c2.cp.kegg.version 7.0.symbols). The significant pathways for gene sets are listed in order of significance in [Table 4](#table4-1758835920927635){ref-type="table"}. Multiple pathways, including glutathione metabolism, leukocyte transendothelial migration, chemokine signaling pathway, NOTCH signaling pathway, Toll-like receptor signaling pathway, hematopoietic cell lineage, vascular endothelial growth factor (VEGF) signaling pathway, and B-cell receptor signaling pathway, were significant in *ANXA5* high-expression phenotype. Enrichment plots were shown in [Figure 7](#fig7-1758835920927635){ref-type="fig"}. Our results indicate that *ANXA5* high-expression may be associated with AML progression and sensitivity to chemotherapeutic agents such as GO.

###### 

Gene set enrichment analysis demonstrated the correlation between *ANXA5* expression phenotype.

![](10.1177_1758835920927635-table4)

  Name                                                 ES       NES      NOM *p*-value   FDR *q*-value   Leading edge
  ---------------------------------------------------- -------- -------- --------------- --------------- --------------------------------
  KEGG_FC_GAMMA_R\_MEDIATED_PHAGOCYTOSIS               0.6027   2.0824   0               0.0069          tags=39%, list=13%, signal=44%
  KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES   0.706    2.0465   0.0021          0.0073          tags=20%, list=2%, signal=20%
  KEGG_GLYCOLYSIS_GLUCONEOGENESIS                      0.5859   1.984    0               0.0094          tags=44%, list=19%, signal=54%
  KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION            0.5      1.9654   0               0.0096          tags=32%, list=17%, signal=38%
  KEGG_GLUTATHIONE_METABOLISM                          0.5781   1.9597   0.0021          0.0094          tags=56%, list=24%, signal=74%
  KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY       0.5061   1.9264   0               0.0113          tags=30%, list=13%, signal=34%
  KEGG_CHEMOKINE_SIGNALING_PATHWAY                     0.4926   1.9236   0               0.0104          tags=27%, list=13%, signal=31%
  KEGG_PENTOSE_PHOSPHATE_PATHWAY                       0.6734   1.9087   0.0021          0.0128          tags=65%, list=22%, signal=84%
  KEGG_NOTCH_SIGNALING_PATHWAY                         0.5746   1.9063   0               0.0125          tags=40%, list=19%, signal=50%
  KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY            0.5263   1.8692   0.002           0.017           tags=47%, list=28%, signal=65%
  KEGG_HEMATOPOIETIC_CELL_LINEAGE                      0.5143   1.8585   0.004           0.0174          tags=31%, list=11%, signal=34%
  KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION             0.5053   1.8251   0.0084          0.0223          tags=43%, list=27%, signal=58%
  KEGG_VEGF_SIGNALING_PATHWAY                          0.5002   1.8199   0               0.0226          tags=36%, list=16%, signal=42%
  KEGG_ENDOCYTOSIS                                     0.4643   1.8076   0               0.024           tags=38%, list=20%, signal=47%
  KEGG_CELL_ADHESION_MOLECULES_CAMS                    0.4348   1.7818   0.0021          0.0287          tags=31%, list=22%, signal=40%
  KEGG_BETA_ALANINE_METABOLISM                         0.5792   1.7665   0.0066          0.0304          tags=64%, list=35%, signal=97%
  KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM     0.5403   1.7504   0.0104          0.0336          tags=26%, list=8%, signal=28%
  KEGG_PYRUVATE_METABOLISM                             0.5485   1.7417   0.0085          0.0359          tags=41%, list=20%, signal=51%
  KEGG_TRYPTOPHAN_METABOLISM                           0.5075   1.7353   0.0086          0.0365          tags=43%, list=26%, signal=57%
  KEGG_B\_CELL_RECEPTOR_SIGNALING_PATHWAY              0.5245   1.7279   0.0085          0.0379          tags=31%, list=13%, signal=35%

ES, enrichment score; FDR, false discovery rate; NES, normalized enrichment score; NOM, nominal.

![GSEA results showing differential enrichment of genes related to glutathione metabolism, leukocyte transendothelial migration, chemokine signaling pathway, NOTCH signaling pathway, Toll-like receptor signaling pathway, hematopoietic cell lineage, VEGF signaling pathway, and B-cell receptor signaling pathway in pediatric AML with high *ANXA5* expression.\
AML, acute myeloid leukemia; GSEA, gene set enrichment analysis; VEGF, vascular endothelial growth factor.](10.1177_1758835920927635-fig7){#fig7-1758835920927635}

Discussion {#section17-1758835920927635}
==========

The prognosis of pediatric AML has improved tremendously over the last few decades, with the survival rate today reaching approximately 75%.^[@bibr36-1758835920927635]^ Unfortunately, one third of cases eventually relapse.^[@bibr37-1758835920927635]^ Cytarabine- and anthracycline-based induction chemotherapy for AML has been used for 30--40 years and needs to be optimized to prolong survival and increase CR rate without adopting dose escalation.^[@bibr38-1758835920927635]^ Recent progress in the genetic and molecular etiology of leukemia has led to molecular-targeted therapies.^[@bibr39-1758835920927635]^ The first targeted therapy was a combination of all-trans retinoic acid and arsenic trioxide for patients with AML with rearrangement of the retinoic acid receptor.^[@bibr40-1758835920927635]^ Subsequently, fms-related tyrosine kinase 3 (FLT3) inhibitors targeting *FLT3* mutations emerged, but the effective treatment period of any given drug as a single agent was only 2--6 months.^[@bibr41-1758835920927635]^ Therefore, another more broad-spectrum *FLT3* inhibitor, midostaurin, combined with chemotherapy, was approved by the US FDA for use in newly diagnosed patients with AML.^[@bibr42-1758835920927635],[@bibr43-1758835920927635]^ However, patients treated with this regimen still had a high recurrence rate. More recently, inhibitors ivosidenib and enasidenib, targeting *IDH1* and *IDH2* mutations, as well as inhibitors targeting epigenetically related genes such as *EZH2, KDM1A* and *DOT1L* mutations were successively approved by the US FDA.^[@bibr44-1758835920927635]^ These hypomethylated drugs showed good results in specific types of AML, such as patients with mutations in the *TET2* or *p53* genes.^[@bibr45-1758835920927635],[@bibr46-1758835920927635]^ Venetoclax, an inhibitor of *BCL2* gene mutation, has been used in elderly patients with AML.^[@bibr47-1758835920927635]^ The effective rate of single-drug therapy in patients with recurrence was about 20%, and combined with hypomethylated drug therapy, 60%.^[@bibr48-1758835920927635]^ Furthermore, GO can be used in AML induction chemotherapy to improve OS and relapse free survival (RFS) and reduce recurrence rates.^[@bibr26-1758835920927635],[@bibr38-1758835920927635]^ Several clinical trials have evaluated the efficacy of GO in combination with conventional cytotoxic chemotherapy, but some may increase the toxic load. The cytotoxic effect of GO depends heavily on its intracellular trafficking and processing. Previous research has shown that activation of lysosomal functions in primary leukemia cells could enhance the cytotoxicity of GO.^[@bibr49-1758835920927635]^ Therefore, it is necessary to integrate available data for evaluation of this drug.

Further research is required to guide clinical therapy for pediatric patients with AML, and to identify molecular predictive markers of efficacy. The present study analyzed the RNA-sequencing data from TARGET databases with a focus on pediatric AML. We evaluated the correlation among *ANXA5* expression with clinical characteristics between GO and no-GO groups, and further described the differences in survival to estimate the clinical outcome of *ANXA5* in patients with different chemotherapy regimens. Furthermore, the results suggest that high *ANXA5* expression correlates with an adverse outcome in patients with pediatric AML treated with conventional chemotherapy. However, patients undergoing conventional chemotherapy combined with GO are able to overcome the adverse effect of high *ANXA5* expression. Our findings suggest that *ANXA5* can be considered a predictive molecule to design personalized therapy for individual patients. Patients with high expression of *ANXA5* will benefit more from GO treatment in pediatric AML. Of note, we made an effort to study the effect of knockdown *ANXA5* on AML cells lines using specific siRNA. *ANXA5* was decreased upon siRNA knockdown; however, it did not significantly alter the expression of CD33. Therefore, *ANXA5* may affect the efficacy of GO *via* an indirect mechanism, and high-throughput sequencing bioinformatics analysis helps to clarify the potential biological implications of this work. We noticed that the expression of *ANXA5* was positively correlated with certain immune-related genes that were crucial for leukemogenesis and immune regulatory functions in AML. Functional enrichment analyses indicated that *ANXA5* was enriched mainly in neutrophil activation, neutrophil-mediated immunity, phagocytosis, lysosomal lumen, immunoglobulin binding, cytokine receptor activity, and signaling pattern recognition receptor activity. GSEA further revealed that 20 pathways were enriched, and primarily involved the following: glutathione metabolism, leukocyte transendothelial migration, chemokine signaling pathway, and hematopoietic cell lineage. In addition, other pathways such as the NOTCH signaling pathway, Toll-like receptor signaling pathway, and VEGF signaling pathway were also related to leukemia.

Pediatric AML lacks an effective prognostic marker to guide the selection of appropriate treatment. In previous research, the expression level of annexin family members predicted clinical outcomes with regard to different variables in combination with clinical characteristics, many of which are frequently dysregulated in human cancers. Tyagi *et al.* demonstrated that patients with AML with high levels of annexin-V expression had significantly inferior OS in univariate analysis. It was also revealed that high apoptosis may be associated with a high-risk phenotype of disease.^[@bibr50-1758835920927635]^ Several studies have reported that *ANXA5* stimulates reduction of interleukin-6 production in bone-marrow-derived macrophages *in vitro*, reduces the infarcted area after ischemia-reperfusion injury, and improves cardiac function by inhibiting cardiac inflammatory response.^[@bibr51-1758835920927635]^ *ANXA5* improves diagnostic efficiency of conventional biomarkers in predicting mortality in patients with heart failure.^[@bibr52-1758835920927635]^ *ANXA5* increases the phosphorylation level of ERK, and ERK inhibitors reverse the activation of *ANXA5* by the ERK/Nrf2 pathway.^[@bibr53-1758835920927635]^ Linke B *et al.* suggested that manipulating annexin family members mediated immunosuppression may benefit patients with cancer or autoimmune diseases and chronic inflammation.^[@bibr54-1758835920927635]^ *ANXA5* was associated with monocyte differentiation, which correlates with favorable clinical outcome in AML.^[@bibr25-1758835920927635],[@bibr55-1758835920927635]^ In addition, *ANXA5* is highly expressed in cells with barrier functions, including vascular endothelium and placental trophoblast cells, and binds to lipopolysaccharide, reducing its endotoxin activity.^[@bibr56-1758835920927635]^ Since *ANXA5* has an influential biological role based on these findings, we propose *ANXA5* as a predictive molecular marker to guide treatment choice in pediatric AML.

Taken together, the results of this study indicate that *ANXA5* produces different prognostic outcomes in different treatment groups of pediatric AML, and patients with high *ANXA5* expression benefit from GO therapy. Our analysis was based on information obtained from the TARGET database, and strengths of the trial included its strong eligibility criteria and a uniform treatment regimen according to standard guidelines. Despite the fact that our results provide a novel therapeutic option for pediatric AML, there are still certain limitations. Our analysis is a retrospective study design, and so the accuracy rate may drop in small-sample cases. This work is based on the results of an RNA-sequencing dataset, and more biological insights remain to be explored. Furthermore, whether this scheme is applicable to adult AML needs to be confirmed by research and practice.

In summary, our research results indicate that the curative effect of GO treatment may be closely related to the level of *ANXA5* expression regulation in pediatric AML. This will improve risk stratification and decision-making regarding treatment options. Furthermore, overexpression of *ANXA5* may circumvent poor outcomes from chemotherapy combined with GO. This discovery may further benefit investigations of the therapeutic direction to guide optimal treatment regimens for individual patients.
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